Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on November 12, 2021, reporting events as of November 11, 2021. The filing serves to announce the Company's financial results for the quarter ended September 30, 2021, and other corporate updates via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the financial results are detailed in the press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
No specific material changes versus the prior comparable period are quantified in this document. The filing indicates that the Company issued a press release containing these results, but the text of the release is not present in the input.
Guidance, Outlook, and Risks
The filing notes the issuance of a press release regarding financial results and "other recent corporate updates." However, the text does not provide specific details on management commentary, future guidance, risks, contingencies, or unusual items. The information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (Ticker: RPHM), not Onkure Therapeutics, Inc.
- Review Exhibit 99.1 (Press Release dated November 11, 2021) for actual financial figures for the quarter ended September 30, 2021.
- Confirm the Company's status as an emerging growth company.
- Check for any subsequent filings that may incorporate the press release information by reference.